Tadimax® (Tadimax® )

Composition Pharmacodynamics Indications Carefully Contraindications Dosing and Administration Side effects Form release / dosage
Read on
Similar drugsTo uncover
Dosage form: & nbspfilm-coated tablets
Composition:

For one tablet:

active components: 371.3 mg of a thick aqueous extract (14.5: 1) from a mixture of: leaf krunum 2 g, rhizome anemarens 0.666 g, bark crust 0.666 g, herbaceous leaves grass 0.666 g, peach seeds 0.083 g, alismatis rhizomes 0.830 g, pion roots 0.500 grams g, bark cinnamon 0.0083 g;

auxiliary components: silicon dioxide colloid 0.055 g, starch 0.220 g, magnesium stearate 0.0065 g, hypromelose 0.007 g, talc 0.007 g, titanium dioxide 0.001 g, macrogol 6000 0.0015 g, iron oxide red (E 172) 0.0003 g, oxide iron black (E 172) 0.0004 g.

Description:

Tablets with a facet, biconvex oval, covered with a shell of brown color. The core is brown, on a brown cut with numerous small yellow patches.

Pharmacotherapeutic group:Prostate hyperplasia is a benign treatment of plant origin
ATX: & nbsp
  • Other drugs for the treatment of benign prostatic hyperplasia
    • Pharmacodynamics:The drug has anti-inflammatory, analgesic, moderate angioprotective action.
    Indications:

    AT complex therapy for the elimination of dysuric disorders, with benign prostatic hyperplasia of the I and II stages.

    Contraindications:

    Hypersensitivity to the components of the drug, severe violations of the liver.

    Pregnancy and lactation:

    The use of the drug in women is not provided.

    Dosing and Administration:

    Inside 2 tablets 3 times a day after meals. The drug should be taken according to the following scheme: 3 courses of 7 days of intake with breaks between courses of 7 days.

    The duration of treatment is determined by the doctor.

    Side effects:

    Allergic reactions are possible.

    In 5% of cases at the beginning of the drug in patients, a burning sensation in the anus can occur. This phenomenon occurs in the process of taking the drug.

    Overdose:

    Cases of overdose of TADIMAX® are not registered.

    Interaction:

    Not described.

    Effect on the ability to drive transp. cf. and fur:

    The drug does not affect the ability to drive vehicles and engage in other potentially hazardous activities that require increased concentration and speed of psychomotor reactions.

    Form release / dosage:Film-coated tablets.
    Packaging:

    21 tablets in aluminum blisters.

    For 2 or 3 blisters together with instructions for medical use are placed in a cardboard box.

    Storage conditions:

    AT dry, protected from light, at a temperature of 15 to 25 ° C.

    Keep out of the reach of children.

    Shelf life:

    3 years.

    Do not use after the expiry date printed on the package.

    Terms of leave from pharmacies:On prescription
    Registration number:LP-002170
    Date of registration:02.08.2013
    Date of cancellation:2018-08-02
    The owner of the registration certificate:Danafa Pharmaceutical Joint Stock Company Danafa Pharmaceutical Joint Stock Company Vietnam
    Manufacturer: & nbsp
    Representation: & nbspDominanta-Service CJSCDominanta-Service CJSC
    Information update date: & nbsp01.02.2016
    Illustrated instructions
      Instructions
      Up